Valneva Se

Valneva to Participate in Multiple Events at the 26th World Vaccine Congress in Washington DC

Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial

Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program

Valneva Reports Full Year 2025 Audited Consolidated Financial Results

Valneva to Report Full Year 2025 Consolidated Financial Results on March 18, 2026